CTLA4 and cancer: Considering that the cardiotoxic effects observed in the animal model could be underestimated due to the reduced binding of Ipilimumab to the mouse CTLA-4 with respect to the human protein, these results highlight the urgent need of cardiac function assessment and monitoring in cancer patients following Nivolumab and Ipilimumab to prevent severe cardiac outcomes.